TMER1 i
Alternative Names: CT-3001; TMER1-iLatest Information Update: 07 Feb 2025
At a glance
- Originator Crossignal Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action GPR35 protein antagonists; Hippo signaling pathway modulators; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; YAP-signaling protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 20 Sep 2024 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy)(PO) (Crossignal Therapeutics pipeline, September 2024) (NCT06598007)
- 02 Sep 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy) (PO), prior to September 2024 (Crossignal Therapeutics pipeline, September 2024)
- 05 Apr 2024 Preclinical trials in Solid tumours in USA (PO), prior to April 2024